View our Rivaroxaban products

Biochemistry of Rivaroxaban

  • Molecular mass: 436 D
  • Plasma half-life: 7-11h
  • Peak plasma time: 2-4 hours after oral administration
  • Bioavailability: 80-100%
  • Composition: C19H18CIN3O5S

Clinical Aspects of Rivaroxaban

Rivaroxaban (Xarelto®) is an anticoagulant drug from the group of direct oral anticoagulants (DOAC). It is an oxazolidinone derivative. Different from the indirect anticoagulants (heparins, fondaparinux, danaparoid-sodium) DOACs do not need a co-factor (antithrombin) for their anticoagulant activity. If monitoring of anticoagulation therapy or an individual dose setting is necessary, a functional anti-factor Xa chromogenic assay (e.g. Chromogenix Coamatic® Heparin) should be used. In this assay, plasma spiked with Xarelto® has to be used for generation of a standard curve.

Clinical or Research use of Rivaroxaban

  • Prevention of venous thromboembolic events (VTE) in adult subjects who have undergone elective hip or knee replacement surgery
  • Prophylaxis of ischemic stroke and systemic embolism in subjects with non-valvular atrial fibrillation (NVAF)
  • Acute and long-term treatment of subjects with deep vein thrombosis (DVT) and pulmonary embolism (PE)

View our Rivaroxaban products

Search this site for Rivaroxaban